These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 17472825)

  • 1. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
    Makus KG; McCormick J
    Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
    Andermann F; Duh MS; Gosselin A; Paradis PE
    Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
    LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
    Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
    Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
    Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic substitution in the treatment of epilepsy: patient and physician perceptions.
    Berg MJ; Gross RA; Haskins LS; Zingaro WM; Tomaszewski KJ
    Epilepsy Behav; 2008 Nov; 13(4):693-9. PubMed ID: 18589000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
    Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
    Berg MJ; Gross RA; Tomaszewski KJ; Zingaro WM; Haskins LS
    Neurology; 2008 Aug; 71(7):525-30. PubMed ID: 18695164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy.
    McAuley JW; Chen AY; Elliott JO; Shneker BF
    Epilepsy Behav; 2009 Jan; 14(1):113-7. PubMed ID: 18768168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
    Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD
    JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
    Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
    Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
    Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current approaches to the use of generic antiepileptic drugs.
    Krämer G; Biraben A; Carreno M; Guekht A; de Haan GJ; Jedrzejczak J; Josephs D; van Rijckevorsel K; Zaccara G
    Epilepsy Behav; 2007 Aug; 11(1):46-52. PubMed ID: 17537678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.
    Hartung DM; Middleton L; Svoboda L; McGregor JC
    CNS Drugs; 2012 Aug; 26(8):707-16. PubMed ID: 22731934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
    Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY
    Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs.
    Bautista RE; Gonzales W; Jain D
    Epilepsy Res; 2011 Jun; 95(1-2):158-67. PubMed ID: 21530177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of antiepileptic drug substitutions on epileptic events requiring acute care.
    Rascati KL; Richards KM; Johnsrud MT; Mann TA
    Pharmacotherapy; 2009 Jul; 29(7):769-74. PubMed ID: 19558250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are generic drugs really inferior medicines?
    Moore N; Berdaï D; Bégaud B
    Clin Pharmacol Ther; 2010 Sep; 88(3):302-4. PubMed ID: 20725079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
    Das S; Jiang X; Jiang W; Ting TY; Polli JE
    Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.